Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post–allogeneic HCT

Blood

Volumn 129, Issue 2, 2017, Pages 162-170

  Zaid, Mohammad Abu ^a,b   Wu, Juan ^c   Wu, Cindy ^c   Logan, Brent R ^d   Yu, Jeffrey ^a,b   Cutler, Corey ^e   Antin, Joseph H ^e   Paczesny, Sophie ^a,b,f   Choi, Sung Won ^f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c EMMES CORPORATION   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CXCL9 CHEMOKINE; FICOLIN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; METHOTREXATE; RAPAMYCIN; SUPPRESSION OF TUMORIGENICITY 2; TACROLIMUS; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; TUMOR MARKER;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DEATH; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; ADVERSE EFFECTS; ALLOGRAFT; ALLOTRANSPLANTATION; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; ALLOGRAFTS; AREA UNDER CURVE; BIOMARKERS, TUMOR; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; METHOTREXATE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SIROLIMUS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 85018440780     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-08-735324     Document Type: Article

References (31)

1. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529-539.
2. Ponce DM, Hilden P, Mumaw C, et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2015;125(1): 199-205.
3. McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood. 2015;126(1):113-120.
4. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-6708.
5. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012;119(16):3854-3860.
6. Harris AC, Ferrara JLM, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012;119(12):2960-2963.
7. Hansen JA, Hanash SM, Tabellini L, et al. A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(9):1323-1330.
8. Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15(13):1451-1459.
9. Kitko CL, Levine JE, Storer BE, et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood. 2014;123(5):786-793.
10. Yu J, Storer BE, Kushekhar K, et al. Biomarker panel for chronic graft-versus-host disease. J Clin Oncol. 2016;34(22):2583-2590.
11. Akil A, Zhang Q, Mumaw CL, et al. Biomarkers for diagnosis and prognosis of sinusoidal obstruction syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(10): 1739-1745.
12. Cutler C, Logan B, Nakamura R, et al. Tacrolimus/ sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372-1377.
13. Fiema B, Harris AC, Gomez A, et al. High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease. J Vis Exp. 2012(68).
14. Brinkmann CR, Jensen L, Dagnæs-Hansen F, et al. Mitochondria and the lectin pathway of complement. J Biol Chem. 2013;288(12): 8016-8027.
15. Iwahana H, Yanagisawa K, Ito-Kosaka A, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem. 1999;264(2):397-406.
16. Zhang J, Ramadan AM, Griesenauer B, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med. 2015;7(308):308ra160.
17. Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001;194(4):398-405.
18. Menke J, Zeller GC, Kikawada E, et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol. 2008;19(6):1177-1189.
19. Piper KP, Horlock C, Curnow SJ, et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood. 2007;110(12):3827-3832.
20. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol. 2003;31(10):897-902.
21. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet1 cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood. 2009;113(15):3620-3630.
22. Westekemper H, Meller S, Citak S, et al. Differential chemokine expression in chronic GVHD of the conjunctiva. Bone Marrow Transplant. 2010;45(8):1340-1346.
23. Croudace JE, Inman CF, Abbotts BE, et al. Chemokine-mediated tissue recruitment of CXCR31 CD41 T cells plays a major role in the pathogenesis of chronic GVHD. Blood. 2012; 120(20):4246-4255.
24. Levine JE, Braun TM, Harris AC, et al; Blood and Marrow Transplant Clinical Trials Network. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2(1):e21-e29.
25. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113(16):3865-3874.
26. Kariminia A, Holtan SG, Ivison S, et al. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR31 NK cells. Blood. 2016;127(24): 3082-3091.
27. Paczesny S, Abu Zaid M. CXCL10: most consistent cGVHD biomarker? Blood. 2016; 127(24):2950-2951.
28. Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656-1665.
29. McDonald GB. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. Blood. 2016;127(12):1544-1550.
30. MacMillan ML, Robin M, Harris AC, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21(4):761-767.
31. Holtan SG, MacMillan ML. A risk-adapted approach to acute GVHD treatment: are we there yet? Bone Marrow Transplant. 2016;51(2): 172-175.